The Growing Challenge of Chronic Kidney Disease: An Overview of Current Knowledge.
Rikke Borg, Nicholas Carlson, Jens Søndergaard...
https://pubmed.ncbi.nlm.nih.gov/36908289/Actively Recruiting
Led by Cardenal Herrera University · Updated on 2025-12-30
250
Participants Needed
1
Research Sites
74 weeks
Total Duration
Researchers are evaluating the relationship between adiposopathy, a malfunction of fat tissue, and chronic kidney disease CKD, a condition where kidney function progressively worsens. This study focuses on patients with CKD stages 1 to 4 who also have type 2 diabetes, cardiovascular diseases, or obesity. The study aims to understand how treatment with glucagon-like peptide-1 receptor agonists GLP-1RA, such as semaglutide and tirzepatide, affects adiposopathy and related kidney and heart risks. CKD progression is linked to increased cardiovascular risk, especially in severe stages requiring dialysis, and adiposopathy may worsen this risk through inflammation. Participants will be in one of several groups receiving different treatments weekly subcutaneous injections of GLP-1RA semaglutide or tirzepatide with dose escalation, daily oral SGLT2 inhibitors, or other standard CKD care medications not involving GLP-1RA or SGLT2 inhibitors. The treatment phase lasts 16 months, during which changes in adipose tissue thickness around organs and kidney function will be monitored using ultrasound and blood tests. Throughout the 16 months, participants will undergo evaluations including ultrasound measurements of various fat tissue areas, blood tests for markers like leptin and adiponectin, and urine tests for kidney injury indicators. Researchers will track changes in fat tissue distribution and kidney function to assess treatment effects. Participants will provide informed consent and be monitored periodically to measure the study outcomes and safety.
CONDITIONS
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
A
Ana Checa-Ros, MD, PhD
L
Luis D'Marco, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Cardenal Herrera University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 16 months
Participants who undergo routine care with GLP-1 receptor agonists, SGLT2 inhibitors, tirzepatide, or other standard treatments for chronic kidney disease and diabetes are observed to assess clinical, morphometric, and biochemical changes related to adiposopathy.
Regular visits to monitor changes over 16 months
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Rikke Borg, Nicholas Carlson, Jens Søndergaard...
https://pubmed.ncbi.nlm.nih.gov/36908289/Dario Giugliano, Maria Ida Maiorino, Giuseppe Bellastella...
https://pubmed.ncbi.nlm.nih.gov/31373167/Mădălina Ioana Moisi, Simona Gabriela Bungau, Cosmin Mihai Vesa...
https://pubmed.ncbi.nlm.nih.gov/34441451/Muhammad Zia Khan, Moinuddin Syed, Mohammed Osman...
https://pubmed.ncbi.nlm.nih.gov/32444271/Rada Artzi-Medvedik, Robert Kob, Paolo Fabbietti...
https://pubmed.ncbi.nlm.nih.gov/33008306/Lekha K George, Santhosh K G Koshy, Miklos Z Molnar...
https://pubmed.ncbi.nlm.nih.gov/28765150/Kyle J Foreman, Neal Marquez, Andrew Dolgert...
https://pubmed.ncbi.nlm.nih.gov/30340847/Luciene R Carraro-Lacroix, Gerhard Malnic, Adriana C C Girardi
https://pubmed.ncbi.nlm.nih.gov/19776173/Elaine Ku, Benjamin J Lee, Jenny Wei...
https://pubmed.ncbi.nlm.nih.gov/30898362/Li Zhao, Wenxin Li, Panpan Zhang...
https://pubmed.ncbi.nlm.nih.gov/38378894/Cardenal Herrera University
Lead Sponsor